Pyrostigmine therapy in a patient with VAMP1-related congenital myasthenic syndrome.
Neuromuscul Disord
; 30(7): 611-615, 2020 07.
Article
em En
| MEDLINE
| ID: mdl-32616363
ABSTRACT
Congenital myasthenic syndrome comprises several genetic disorders that impair neuromuscular junction transmission. Causative mutations occur in at least 30 genes, approximately 6-8% of which are presynaptic. One such gene, VAMP1, encodes vesicle-associated membrane protein-1, which is crucial in the formation and fusion of synaptic vesicles with the presynaptic membrane at the neuromuscular junction. VAMP1 mutations are associated with two main phenotypes a) autosomal recessive congenital myasthenic syndrome and b) autosomal dominant spastic ataxia 1. We report a girl from a consanguineous Saudi family presenting with hypotonia, developmental delay, feeding difficulties and floppiness since birth. Comprehensive genetic testing revealed a homozygous splicing mutation in VAMP1. RT-PCR confirmed the presence of an aberrant transcript causing skipping of exon 2 in the gene.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Brometo de Piridostigmina
/
Síndromes Miastênicas Congênitas
/
Proteína 1 Associada à Membrana da Vesícula
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article